RE:RE:RE:RE:RE:OupsVolume is actually pretty good for THTX, at least, for the first hour and fifteen minutes of trading. The trading this morning int he pre-market was certainly weird but the stock is now back at even versus yesterday, which makes sense since this news today is not really market moving info. And while the stock has been lower in Q3, it is worth remembering that the "selling pressure" can't be that bad since it is still up over 40% YTD.
The biggest issue remains the lack of analyst coverage. THTX has been an abject failure in getting appropriate analyst coverage for many, many years. And they ruined their best opportunity to at least partially fix that when the did the ONO (for any newbies here ONO stands for the "odius necessary offering" THTX did at the beginning of this year - I like that ONO is pronounced Oh No as that seems very appropriate for that offering!).
But my idea of putting big fees into Wall Street's pocket in order to get their NASH asset valued appropriately and fund the phase III trial would solve the lack of analyst coverage as well. Let's hope THTX finds a way to do something like that soon as it is really ridiculous to see the company achieve things medically but not be rewarded by the market for those achievements.
stephanedodier wrote: I am not sure that it's the selling pressure or the lack of interest, the volume is low...